Additionally, the guidelines recognize the increased risk of euglycemic ketoacidosis associated with sodium-glucose co-transporter 2 (SGLT2) inhibitors, a class of medications used in diabetes ...

We sought to describe their association with euglycemic diabetic ketoacidosis (euDKA) in hopes that it will enhance recognition of this potentially life-threatening complication. Research Design ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Risk of severe urinary tract infections was higher with canagliflozin, while dapagliflozin was associated with a lower risk of diabetic ketoacidosis. To TCTMD, Wiviott said there is a large body of ...

Older adults had a lower risk for major adverse CV events than younger adults with SGLT2 inhibitors. SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the ...

and a lower risk of [diabetic ketoacidosis] with dapagliflozin -- the overall risk for safety events, including bone fracture and lower-limb amputation, was similar across the three SGLT2 ...

placebo. Perspective from Shannon C. Scott, DO, FACOFP Use of a sodium-glucose cotransporter 2, or SGLT2, inhibitor combined with calorie restriction resulted in greater rates of type 2 diabetes ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists ...

Prof Eustace said that Ozempic associated euglycemic ketoacidosis and a urinary tract infection were possible “contributing features” in the case. He said Mrs O’Donoghue presented to the ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...